ADXN — Addex Therapeutics Share Price
Last trade - 00:00- CH₣18.48m
- CH₣14.05m
- CH₣1.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.69 | ||
| Price to Tang. Book | 4.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -487.76% | ||
| Return on Equity | -385.02% | ||
| Operating Margin | -1420.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 6.7 | 2.83 | 3.88 | 3.15 | 1.44 | 3.61 | n/a | 23.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Directors
- Vincent Lawton NEC (71)
- Tim Dyer CEO (52)
- Roger Mills EXB (63)
- Robert Lutjens EXB (52)
- Jean-Philippe Rocher EXB (61)
- Raymond Hill NID (75)
- Isaac Manke NID (43)
- Jake Nunn NID (45)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- March 19th, 2007
- Public Since
- May 22nd, 2007
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 122,793,354
- Address
- Chemin des Mines, 9, PLAN-LES-OUATES, 1202
- Web
- https://www.addextherapeutics.com/
- Phone
- +41 228841555
- Auditors
- PricewaterhouseCoopers SA
Upcoming Events for ADXN
Similar to ADXN
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
Evolva Holding
SIX Swiss Exchange
Idorsia
SIX Swiss Exchange
FAQ
As of Today at 19:00 UTC, shares in Addex Therapeutics are trading at CH₣0.15. This share price information is delayed by 15 minutes.
Shares in Addex Therapeutics last closed at CH₣0.15 and the price had moved by +30.87% over the past 365 days. In terms of relative price strength the Addex Therapeutics share price has outperformed the FTSE Global All Cap Index by +22.86% over the past year.
The overall consensus recommendation for Addex Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Addex Therapeutics does not currently pay a dividend.
Addex Therapeutics does not currently pay a dividend.
Addex Therapeutics does not currently pay a dividend.
To buy shares in Addex Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣0.15, shares in Addex Therapeutics had a market capitalisation of CH₣18.48m.
Here are the trading details for Addex Therapeutics:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: ADXN
Based on an overall assessment of its quality, value and momentum Addex Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Addex Therapeutics is CH₣0.16. That is 6.31% above the last closing price of CH₣0.15.
Analysts covering Addex Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CH₣0.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Addex Therapeutics. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +125.71%.
As of the last closing price of CH₣0.15, shares in Addex Therapeutics were trading +99.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Addex Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Addex Therapeutics' management team is headed by:
- Vincent Lawton - NEC
- Tim Dyer - CEO
- Roger Mills - EXB
- Robert Lutjens - EXB
- Jean-Philippe Rocher - EXB
- Raymond Hill - NID
- Isaac Manke - NID
- Jake Nunn - NID